Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease
- PMID: 19217371
- PMCID: PMC3659427
- DOI: 10.1016/j.neuron.2009.01.024
Reprogramming therapeutics: iPS cell prospects for neurodegenerative disease
Abstract
The recent description of somatic cell reprogramming to an embryonic stem (ES) cell-like phenotype, termed induced pluripotent stem (iPS) cell technology, presents an exciting potential venue toward cell-based therapeutics and disease models for neurodegenerative disorders. Two recent studies (Dimos et al. and Ebert et al.) describe the initial characterization of neurodegenerative disease patient-derived iPS cell cultures as proof of concept for the utility of this technology.
References
-
- Abeliovich A, Flint Beal M. Parkinsonism genes: culprits and clues. Journal of neurochemistry. 2006;99:1062–1072. - PubMed
-
- Dimos JT, Rodolfa KT, Niakan KK, Weisenthal LM, Mitsumoto H, Chung W, Croft GF, Saphier G, Leibel R, Goland R, et al. Induced Pluripotent Stem Cells Generated from Patients with ALS Can Be Differentiated into Motor Neurons. Science (New York, NY 2008 - PubMed
-
- Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, et al. Transplantation of embryonic dopamine neurons for severe Parkinson’s disease. The New England journal of medicine. 2001;344:710–719. - PubMed
-
- Hanna J, Wernig M, Markoulaki S, Sun CW, Meissner A, Cassady JP, Beard C, Brambrink T, Wu LC, Townes TM, et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science (New York, NY. 2007;318:1920–1923. - PubMed
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
